Colon/Rectal Cancer Clinical Trials in Georgia

Cancer Type = Colon/Rectal Cancer

Cancer Type = Colon/Rectal Cancer

There are currently 21 active Colon/Rectal Cancer clinical trials in Georgia.
2.
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Cancer Type
Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03849469
Protocol IDs
XmAb22841-01
NCI-2019-02498
DUET-4
3.
A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Skin Cancer (Non-Melanoma), Thyroid Cancer, Unknown Primary
NCI ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
4.
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03415126
Protocol IDs
ASN007-101
NCI-2018-00820
5.
NCORP Trial
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03673501
Protocol IDs
DCC-2618-03-002
NCI-2019-00046
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
7.
NCORP Trial
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT02921256
Protocol IDs
NRG-GI002
NCI-2016-00222
Treatment Sites (1)
10.
NCORP Trial
A Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High Risk Anal Cancer
Cancer Type
Colon/Rectal Cancer, Skin Cancer (Non-Melanoma)
NCI ID
NCT03233711
Protocol IDs
EA2165
EA2165
NCI-2017-01347
Treatment Sites (1)
11.
12.
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
Cancer Type
Colon/Rectal Cancer, Head and Neck Cancer, Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03783936
Protocol IDs
HCRN GI17-319
NCI-2018-03813
13.
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Cancer Type
Colon/Rectal Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary
NCI ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
14.
NCORP Trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type
Appendix Cancer, Bone and Soft Tissue (including Sarcoma), Brain Cancer , Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (1)
15.
NCORP Trial
Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03516942
Protocol IDs
EAQ162CD
EAQ162CD
ECOG-ACRIN-EAQ162CD
NCI-2018-00151
Treatment Sites (1)
16.
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03043313
Protocol IDs
ACCRU-GI-1617
NCI-2017-01107
17.
18.
NSABP Patient Registry and Biospecimen Profiling Repository
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT01793805
Protocol IDs
NSABP MPR-1
20.
Phase I Integrated Biomarker Trial of VX15 / 2503 in Combination with Ipilimumab or Nivolumab in Patients with Pancreatic and Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Pancreatic Cancer, Unknown Primary
NCI ID
NCT03373188
Protocol IDs
Winship4142-17
NCI-2017-01618
IRB00098707
21.
Phase Ib Trial of Pembrolizumab and XL888 in Patients with Advanced Gastrointestinal Malignancies
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03095781
Protocol IDs
Winship3321-16
NCI-2016-01594
IRB00087397
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.